The Hypothesis: PKM2 Dimerization as the Pro-SASP Metabolic Command Center

I propose that the 'Warburg-like' shift in senescent cells is not merely an adaptive survival mechanism to manage redox stress, but a programmed metabolic-transcriptional bridge mediated by the Pyruvate Kinase M2 (PKM2) isoform. Specifically, I hypothesize that senescence-inducing stimuli trigger the transition of PKM2 from its active tetrameric form to a low-activity dimeric state. This transition acts as a 'dual-lock' for the Senescence-Associated Secretory Phenotype (SASP):

1. Metabolic Shunt: By slowing pyruvate production, dimeric PKM2 diverts glycolytic intermediates into the Pentose Phosphate Pathway (PPP) and the Hexosamine Biosynthetic Pathway (HBP), providing the NADPH and protein glycosylation precursors required for the massive secretory burden of SASP [https://pubs.acs.org/doi/10.1021/pr501221g].
2. Transcriptional Co-activation: In its dimeric form, PKM2 translocates to the nucleus where it acts as a non-canonical co-factor for NF-κB and HIF-1α, directly driving the transcription of IL-6 and IL-8, independent of its enzymatic function [https://pmc.ncbi.nlm.nih.gov/articles/PMC11492308/].

Mechanistic Reasoning

Current literature often views the senescent Warburg shift as 'broken' metabolism or a side effect of mitochondrial dysfunction [https://pmc.ncbi.nlm.nih.gov/articles/PMC7767554/]. However, the persistence of SASP even under nutrient-depleted conditions suggests a hardwired prioritization of secretion over homeostatic maintenance.

I suggest that the observed NAD+ decline [https://pmc.ncbi.nlm.nih.gov/articles/PMC7767554/] and SIRT3/5 loss act as the primary triggers for PKM2 dimerization via post-translational modifications (likely acetylation or oxidation). This 'Warburg Blind Spot' hides a sophisticated partitioning of flux: by bottlenecking at the PKM2 step, the cell prevents mitochondrial over-reduction and subsequent ROS-induced apoptosis, while simultaneously fueling the endoplasmic reticulum (ER) expansion necessary for secretion through HBP-derived UDP-GlcNAc.

Furthermore, the 'Anti-Warburg' effect observed in some oncogene-induced senescence (OIS) models [https://doi.org/10.1002/pmic.201200298] might represent a failure of this PKM2 switch, leading to rapid metabolic exhaustion rather than the 'stable' chronic inflammation characteristic of replicative senescence.

Testability and Falsification

This hypothesis can be tested through several avenues:

• PKM2 Stabilization: Treating senescent cells with small-molecule PKM2 activators (e.g., TEPP-46) that force PKM2 into a tetrameric state.
  • Prediction: Tetramerization will restore mitochondrial pyruvate flux but significantly suppress SASP secretion and NF-κB target gene expression, even if mTORC1 remains active.
• Nuclear Exclusion: Utilizing PKM2 mutants that lack the nuclear localization signal (NLS).
  • Prediction: These cells will exhibit high glycolytic flux (due to cytoplasmic dimeric PKM2) but will fail to sustain the inflammatory arm of the SASP.
• Metabolic Tracing: Using [13C]-glucose tracing to measure flux into the Hexosamine Biosynthetic Pathway specifically during the transition to senescence.

Discussion: Moving Beyond Waste Products

If the senescent secretome were merely a metabolic byproduct [2026-03-11 discussion], inhibiting glycolysis would induce cell death. I argue instead that the PKM2 dimer creates a 'safe' metabolic harbor. By targeting the state of PKM2 rather than the rate of glycolysis, we may find a way to decouple senescence from its pathological systemic effects without the toxicity associated with total metabolic inhibition [https://pmc.ncbi.nlm.nih.gov/articles/PMC12920127/].